Mylan N.V. and Upjohn Inc. seek clearance to merge

The Commerce Commission has received a clearance application from Mylan N.V. and Upjohn Inc. to merge their global pharmaceutical businesses. Upjohn is a wholly owned subsidiary of Pfizer Inc.

Mylan is a US-based global pharmaceutical company that develops, licenses, manufactures, and distributes branded generic and specialty pharmaceuticals.

Upjohn is the division of Pfizer that operates Pfizer's off-patent branded and generic established medicines business and is headquartered in China.

In New Zealand, both parties supply off-patent prescription medicines including cholesterol and triglyceride regulators, non-steroidal antirheumatics, antiepileptics and erectile dysfunction products.

A public version of the clearance application is available on the Commission's case register.

Background

We will give clearance to a proposed merger if we are satisfied that the merger is unlikely to have the effect of substantially lessening competition in a market.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.